Optum guides members and providers through important upcoming formulary updates. See multiple tabs of linked spreadsheet for Select, Premium & UM Changes.
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
December 16, 2019 - Pfizer and Astellas Pharma announced the FDA approval of Xtandi (enzalutamide), for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).
Return to publications